which Bristol Myers Squibb acquired in March 2024. At Karuna, he served as Senior Vice President of Regulatory Affairs and Quality Assurance, where he oversaw the regulatory submission and ultimate ...

An Investigational New Drug application for the Nectin4/TROP2 ADC is planned for submission to the U.S. Food and Drug Administration in ... played an integral role in its acquisition by Bristol Myers ...

The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.

Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...

The move reflects Novartis’ efforts to strengthen its radiopharmaceutical pipeline with an SSTR2 drug, following the lead of both Eli Lilly and Bristol Myers Squibb ... which the Food and Drug ...

The US Food and Drug Administration approved Augtyro in 2023 for the treatment of ROS1-positive advanced NSCLC. Earlier this year, the FDA also approved the drug for adult and pediatric patients 12 ...

Over 30 years, Cortes has led or co-authored hundreds of studies, including many trials of landmark drugs to treat chronic ...

Bristol Myers Squibb on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its Augtyro cancer drug in a pair of indications.

Topline data from Phase 2 CM24 pancreatic cancer trial expected by the end of 2024New CM24 biomarkers data presented during the third quarter of ...

The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...

Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...

Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...